RoslinCT to Present at 2023 Cell & Gene Meeting on the Mesa
EDINBURGH, UK, and BOSTON, USA, October 04, 2023 – RoslinCT announced today that Barbara Ressler, VP of Manufacturing Process Sciences at RoslinCT Boston, will present at the annual Cell & Gene Meeting on the Mesa to be held October 10-12 in Carlsbad, California and live-streamed globally.
“I’m honored to be presenting at the Cell & Gene Meeting on the Mesa this year. Our team at RoslinCT is dedicated to advancing manufacturing processes that will drive the future of cell and gene therapies. This event provides a valuable platform to share insights and collaborate with industry leaders, accelerating progress in this transformative field.” said Barbara.
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring more than 120 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.
The following are specific details regarding RoslinCT’s presentation at the conference:
Date: Wednesday, October 11th, 2023
Time: 9:45 am PT
Location: Park Hyatt Aviara Resort, 7100 Aviara Resort Dr., Carlsbad, CA 92011
Virtual attendance is available which includes a livestream of RoslinCT’s presentation and the ability to view all conference sessions on-demand. Please visit https://meetingonthemesa.com for full information including registration.
Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Savannah Bryant at firstname.lastname@example.org and interested media should contact Stephen Majors at email@example.com.
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones. These include being among one of the first in the world to produce clinical-grade human pluripotent stem cells. In collaboration with the partners, RoslinCT also developed the first CRISPR-edited cell therapy product for a major inherited disorder, taking it from early development to commercialization.
Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation.
With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide.
Discover more about our services at www.roslinct.com.
Media Contact Information:
Senior Director of Strategic Marketing